AdWiki Webring Site
| SELECT YOUR LANGUAGE:
ar  |
id  |
bg  |
ca  |
ceb  |
cs  |
da  |
de  |
et  |
en  /  /  |
es  |
eo  |
fr  |
gr  |
he  |
hr  |
it  |
ko  |
lt  |
hu  |
nl  |
ja  |
no  |
pl  |
pt  |
ru  |
ro  |
sk  |
sl  |
sr  |
fi  |
sv  |
te  |
tr  |
uk  |
zh 
Tocilizumab
From Wikipedia, the free encyclopedia
Tocilizumab (under development by Roche and Chugai under the trade name Actemra) is a humanized monoclonal antibody against IL-6R (interleukin-6 receptor) used as an immunosuppressive drug.
As of 2008, it is currently under regulatory review by the United States Food and Drug Administration (US FDA), the European Medicines Agency (EMA) and Australia's Therapeutic Goods Authority is conduction trials and will then assess an application to have the drug added to the Pharmaceutical Benefits Scheme.
It has been proposed for use in Castleman's disease.[1] Data presented on 28 October 2008 shows that this medication can be effective in adjunct therapy for treatment of rheumatoid arthritis. [1]
[edit] References
|
Immunomodulators – Immunosuppressants – Immunosuppressive drugs (L04) |
|
Intracellular
(signal initiation) |
|
|
| Extracellular |
|
|
|
|
|
Serum target
(noncellular)
|
|
|
|
Cellular target
|
CD3 ( Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 ( Clenoliximab, Keliximab, Zanolimumab) · CD11a ( Efalizumab) · CD18 ( Erlizumab) · CD20 ( Afutuzumab, Ocrelizumab, Pascolizumab) · CD23 ( Lumiliximab) · CD40 ( Teneliximab, Toralizumab) · CD62L/L-selectin ( Aselizumab) · CD80 ( Galiximab) · CD147/Basigin ( Gavilimomab, Ziralimumab) · CD154 ( Ruplizumab)
BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab)
IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab)
T-lymphocyte ( Zolimomab aritox)
|
|
|
Unsorted
|
Atlizumab, Atorolimumab, Cedelizumab, Dorlimomab aritox, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Lebrilizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab
|
|
|
|
|
|
|
|
|
|
|
|
|
Intracellular
(signal reception) |
|
|
|
Humanized monoclonal antibodies ("-zu-") |
|
| "-tuzu-" (tumor) |
Afutuzumab, Alemtuzumab, Bevacizumab/ Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab†, Milatuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
|
|
| "-lizu-" (immune system) |
immunosuppressive: Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412
non-immunosuppressive: Ibalizumab†
|
|
| "-bazu-" (bacterial) |
|
|
| "-cizu-" (cardiovascular) |
|
|
| "-nezu-"/"-neuzu-" (nervous system) |
|
|
| "-toxazu-" (toxin as target) |
|
|
| "-vizu-" (viral infections) |
|
|
| "-kinzu-" (interleukin as target) |
|
|
| †Undergoing clinical trials. |
|
Change language: All |
Arabic |
Indonesian |
Bulgarian |
Catalan |
Cebuano |
Czech |
Danish |
German |
Estonian |
English / / |
Spanish |
Esperanto |
French |
Greek |
Hebrew |
Croatian |
Italian |
Korean |
Lithuanian |
Hungarian |
Flemish / Dutch |
Japanese |
Norwegian |
Polish |
Portugues |
Russian |
Romanian |
Slovakian |
Slovenian |
Serbian |
Suomi / Finish |
Swedish |
Iranian |
Turkish |
Ukrainian |
Chinese
MORE LINKS...
Autorem skryptu AdWiki v0.62 (2007) jest husky83
Licencję na skrypt dla strony DAWAJ.INFO posiada dzankes
Wikipedia® jest zarejestrowanym znakiem towarowym Wikimedia Foundation |
